Skip to content
Search

Latest Stories

Pharmacists critical in helping people to practice self-care with confidence: survey

Pharmacists critical in helping people to practice self-care with confidence: survey

People are opting to visit pharmacists for self-care and are conscious of the positive impact it can have on alleviating healthcare system pressures, a new survey has found.

While it is still common for consumers across Europe to seek advice or reassurance from a GP, particularly when symptoms last longer than usual or are worse than normal, almost every second consumer (49%) has chosen to visit a pharmacist rather than a doctor for advice in the last year, even though a consultation was necessary from their point of view.


Around a fifth (19%) have done so multiple times, the survey of 5,000 European consumers, commissioned by consumer health company Kenvue, has found.

In the UK, findings show that pharmacists are a highly valued source of healthcare advice for consumers.

More than a quarter (29%) of those who had chosen to visit a pharmacist rather than a doctor in the last year said this was because they trust their local pharmacist to provide healthcare advice. Additionally, over one third said (35%) said this is where they typically turn to for healthcare advice, compared to 34 per cent who normally seek advice from their GP.

Kenvue said the high level of trust in pharmacists is positive news for healthcare systems more broadly.

Previous research showed that if self-medication were not available, around 120,000 more physicians would be required in Europe or, alternatively, each physician would have to work 2.4 hours longer per day [Association of the European Self-Care Industry, 2021].

This was echoed in the new survey, which found that if self-care treatments were less accessible, most UK consumers would visit a doctor for a prescription instead.

Survey responses indicate that consumers in the UK recognise the positive role that pharmacists and self-care play in building sustainable healthcare systems. Close to half (48%) who prefer to get treatments for minor ailments from a pharmacy said they do so to save doctors’ time.

Results also suggest that consumers would benefit from a greater understanding of the services and advice pharmacists offer, particularly when they feel unsure about what to do.

A quarter of the UK respondents currently choose to visit a doctor for minor ailments simply for reassurance (25%) and 15 per cent would see a doctor for guidance on product choice or dosage – both areas where pharmacists could provide advice and help consumers feel more confident about their self-care choices, the study noted.

“Empowering people to take control of their health is something we strive to do every day through our brands such as Nicorette, Zarbee’s, Benylin and Sudafed, because we know how impactful everyday care can be,” Angeliki Kazantzidi, Head of Marketing for Kenvue in Northern Europe, commented.

“It’s extremely positive to see that consumers in the UK recognise the importance of self-care and the role it can play in our healthcare system. Pharmacists have a crucial role to play as a source of expert healthcare advice and services, helping more consumers to practice self-care with confidence.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less